Japan· JP-1316700Q1050
ナファゾリン硝酸塩
A naphazoline product containing ナファゾリン硝酸塩, registered in Japan by 日新製薬(山形), on the national reimbursement list. The same ATC class is registered in 5 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Naphazoline is registered in 5 of 19 countries.
Countries holding a registration under ATC R01AA08 (naphazoline), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 3 of them publish a price we can compare per daily dose
Naphazoline · ATC R01AA08
5 / 19 countries
- Belgiumprice
- Czechiaprice
- Germany
- Japan
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ナファゾリン硝酸塩
- Manufacturer
- 日新製薬(山形)
- Country
- Japan (JP)
- ATC code
- R01AA08
- ATC class
- Naphazoline
- Defined daily dose
- 0.4 mg, N
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
49 interactions on record for naphazoline.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Naphazoline · interactions on record
49 records
- 6 severe
- 43 moderate
Most severe, free to view
- MethylergometrineG02AB01severe
- DihydroergotamineN02CA01severe
- ErgotamineN02CA02severe
- MethysergideN02CA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Naphazoline in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesDERMFREE ORIGINAL NASALJiangxi Yudexi Pharmaceutical Co., LTD
- BelgiumDeltarhinol Mono 1 mg/mlMelisana
- CzechiaSANORINFARMAK INTERNATIONAL Sp.z.o.o., Varšava
- GermanyDuraultra N SineOmnivision Gmbh
- CanadaALBALONABBVIE CORPORATION
- FinlandCleariElara Pharmaservices Europe Limited
- United KingdomMurine irritation & redness relief 0.012% eye dropsPrestige Brands (UK) Ltd
- IrelandMurine irritation & redness relief, 0.012% w/v, eye drops solutionElara Pharmaservices Europe Limited
Authorised across Europe · EMA
The same active substance is authorised in 18 EEA countries. Names it is sold under:
- Austria · Aconex, Coldan
- Czechia · Sanorin
- Germany · Duraultra N Sine, Rhinex Nasenspray Mit Naphazolin
- Denmark · Cleareyes
- Spain · Centilux
- Finland · Cleari
- United Kingdom (Northern Ireland) · Clear Eyes, Murine Irritation & Redness Relief
- Croatia · Nazol, Proculin
- Hungary · Iridina Due
- Ireland · Murine Irritation & Redness Relief
- Iceland · Cleye
- Italy · Brunizina, Collirio Alfa Decongestionante
- Latvia · Naphthyzinum
- Norway · Cleye
- Romania · Rinofug
- Sweden · Cleari
- Slovenia · Proalkalin
- Slovakia · Sanorin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3a9f9708-f6fb-4d2f-a7e1-b7b29d224864 GET /v1/drugs/3a9f9708-f6fb-4d2f-a7e1-b7b29d224864?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "0.05%1mL",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1316700Q1050",
"category": "外用薬",
"price_yen": 19.1,
"generic_name": "ナファゾリン硝酸塩",
"product_name_jp": null,
"therapeutic_class": "1316",
"transitional_expiry": null
}See everything about naphazoline.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.